1
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
[x] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [FEE REQUIRED]
FOR FISCAL YEAR ENDED: DECEMBER 31, 1996
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934 [FEE REQUIRED]
COMMISSION FILE NO. 0-22958
INTERPORE INTERNATIONAL
(Exact name of registrant as specified in its charter)
CALIFORNIA 95-3043318
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification number)
181 TECHNOLOGY DRIVE, IRVINE, CALIFORNIA 92618-2402
(Address of principal executive offices) (Zip code)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (714) 453-3200
SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
- --------------------- ------------------------
None
SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:
Common stock, no par value
Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [x] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
As of March 20, 1997, the aggregate market value of voting stock of
Interpore International held by non-affiliates was $22,109,000 based upon the
closing price of such stock on The Nasdaq Stock Market. The number of shares
of common stock outstanding as of that date was 6,956,547.
DOCUMENTS INCORPORATED BY REFERENCE
1. Portions of the Company's Proxy Statement for the 1997 Annual Meeting
of Shareholders of Interpore International are incorporated by the
reference into Part III as set forth herein.
================================================================================
2
PART I
ITEM 1. BUSINESS
GENERAL
Interpore International (the "Company") is a biomaterials company that
develops, manufactures and markets synthetic bone graft material for the
orthopaedic, oral and maxillofacial markets. The Company's synthetic bone graft
products are derived from coral using its proprietary manufacturing process
which converts the unique skeletal structures of certain species of coral to
coralline hydroxyapatite, a biocompatible material. Coralline hydroxyapatite
has interconnected porosity, architecture and chemical composition similar to
that of human cancellous bone, and facilitates bone and tissue ingrowth. The
Company's Pro Osteon(R) Implant 500 Coralline Hydroxyapatite Bone Void Filler
("Pro Osteon") was the first synthetic bone graft material to be approved and
marketed as a medical device for orthopaedic applications in the United States.
Pro Osteon has been approved by the United States Food and Drug Administration
(the "FDA") for use with certain acute metaphyseal defects (defects in the wide
part of long bones). In FDA required patient studies, Pro Osteon was shown to
have clinical results comparable to the results of using a patient's own bone,
called an autograft. The Company also distributes hand-held manual instruments
for use in arthroscopic surgeries and titanium dental implant systems.
BUSINESS STRATEGY
The Company's strategy is to capture an increasing share of the market for
bone graft materials by aggressively marketing Pro Osteon, and to develop
technological advances in bone and soft tissue repair products. In furtherance
of this strategy, the Company in 1995 and 1996 established 28 domestic direct
sales territories in areas in which distributors were underperforming. In
addition, in January 1996, the Company hired three experienced international
sales managers responsible for developing an organization of independent dealers
outside the United States. The Company's strategy also involves adding
complementary products that relate to the repair of bone and soft tissue, which
the Company believes will enhance sales of its bone graft materials by providing
a broader product base and by providing more compensation potential for its
sales representatives. The Company is currently focusing its research and
clinical studies on obtaining additional FDA approved indications for Pro Osteon
for use in spinal fusion procedures and for use as a bone void filler for the
iliac crest region of the hip following autograft procedures. The Company also
plans to focus its research efforts on developing new materials with improved
resorption and bone induction characteristics to fulfill a variety of other bone
graft requirements. When appropriate, the Company may enter into strategic
alliances, partnerships or license arrangements with other companies to develop
new products.
In 1996, the Company also made the decision to further focus its
development and operational efforts on its core bone graft materials business by
exploring the sale of its dental business. In September 1996, the Company
entered into a letter of intent to sell the dental business to Friatec AG. The
transaction contemplated by this letter of intent was not consummated within the
exclusive time period and in January 1997, the Company terminated discussions
with Friatec AG and entered into a letter of intent with Steri-Oss, Inc.
Consummation of the transaction is contingent upon certain conditions including
satisfactory completion of due diligence, negotiation of a mutually acceptable
definitive agreement, and the approvals of the boards of directors of the two
companies.
MARKET OVERVIEW
Bone Graft Substitutes. The Company believes that the market for bone
graft materials is significant. A recent market research study indicates that
the current United States market for bone grafts totals over 425,000 procedures
annually, with approximately 46% of the procedures in the spine, 40% in other
orthopaedic procedures, and about 14% in maxillofacial applications.
2
3
According to the Company's internal estimates, the approved indication
for Pro Osteon represents approximately 100,000 procedures annually in the
United States. In order to market Pro Osteon for other indications and thus
gain access to a larger segment of the bone graft market, the Company will have
to receive an Investigational Device Exemption ("IDE") from the FDA allowing the
Company to conduct additional clinical studies and ultimately receive a
Premarket Approval ("PMA") supplement from the FDA for each new indication. In
January 1995, the FDA approved the Company's IDE to commence clinical trials for
the use of Pro Osteon Implant 200 in the cervical spine. Pro Osteon will be used
in conjunction with a rigid titanium bone plate to fuse vertebrae in the neck.
This initial FDA IDE approval covers 60 patients at up to five hospitals in the
United States. In May 1996, the FDA approved the Company's IDE to commence
clinical trials for the use of Pro Osteon Implant 500 to fill the void left by
autograft harvesting procedures in the iliac crest region of a patient's hip.
This pilot study will be performed in conjunction with lumbar spine fusion
procedures involving twenty patients, with ten receiving Pro Osteon as a
backfill material, and ten receiving no backfill material. In the future, the
Company may pursue IDE approval for clinical trials using Pro Osteon as a bone
void filler for other indications. The FDA approval process, however, is very
lengthy and the Company can give no assurance concerning when or whether it will
receive FDA approval to market Pro Osteon for these or any other new
indications. In addition, competition from other bone graft materials may limit
market penetration.
To enter segments of the potential market for orthopaedic bone graft
applications not addressed by the Company's current products, the Company is
working to develop new bone graft materials that have faster resorption,
osteoinductive characteristics that will increase bone formation and increased
strength. No assurance can be given that any such efforts will result in
marketable products.
Dental Implants. According to market research data, the United States
dental implant market totals approximately $100 million. The Company believes,
however, that the growth of this market has slowed, largely due to the lack of
insurance reimbursement for elective procedures involving dental implants.
The domestic dental implant market is fragmented, with more than 20
competitors. Six of these competitors represent approximately 90% of the
market. Over the past few years, there have been significant changes in market
share positions for the major competitors because of new product introductions,
price, customer service and education programs. The Company has seen its share
of this market decline to less than 5% during the last two years due to
increased competition and the absence of major new product line introductions.
Manufacturers competing in the United States market promote their dental
implant products (Class III medical devices) pursuant to 510(k) clearance, an
approval to market a device demonstrated to be substantially equivalent to
certain products which were commercially available prior to May 28, 1976. In
1990, Congress enacted the Safe Medical Device Act of 1990 which required the
FDA to either down-classify these Class III devices to Class I or II, or publish
a date for the call for PMA applications for any remaining Class III devices on
the market. The Company expects that within the next year certain dental
implants will be down-classified to Class II, but others will remain as Class
III. It is probable that some of the Company's dental implants will remain
Class III and that a PMA will be required to continue marketing some or all of
the Company's dental implant products. The Company has been collecting clinical
data to support an expected PMA application. The Company can give no assurance
concerning when or whether it would receive a PMA approval from the FDA for its
dental implant products. If the FDA requires PMA's for new and/or existing
implants, some competitors could face a significant additional barrier to enter
this market since a PMA must include a minimum three years of clinical data to
support product safety and efficacy.
PRODUCTS
Hydroxyapatite Materials.
The Company's current coralline hydroxyapatite product line includes Pro
Osteon, Interpore 200(R) Porous Hydroxyapatite (also called Pro Osteon Implant
200) and orbital implants. These products are derived from coral using a
proprietary ReplamineformTM process. (See "Proprietary Rights") Under this
process, the exoskeleton of marine coral (calcium carbonate) is converted to
coralline hydroxyapatite through a hydrothermal exchange reaction. This
biocompatible material has interconnected porosity, architecture and chemical
composition similar to that of human bone, and facilitates bone and tissue
ingrowth.
3
4
Pro Osteon. Upon PMA approval from the FDA in November 1992, Pro Osteon
was the first commercially available synthetic bone void filler material for
orthopaedic applications in the United States. The FDA approved indication is
for treatment of certain metaphyseal defects. In clinical studies, the use of
Pro Osteon was demonstrated, radiographically and clinically, to have healing
time and complication rates comparable to autograft procedures. The Company is
not aware of any material unfavorable results in the clinical studies for Pro
Osteon. Pro Osteon is available in granular forms and a wide variety of block
configurations up to 30 cc's in total volume. With approximately $800 of
material used in an average procedure, Pro Osteon provides an attractive
alternative to autograft and allograft bone graft materials. To successfully
maintain and increase its market share, the Company will have to continue to
demonstrate its surgical and patient advantages, safety, efficacy, cost
effectiveness and clinical results to physicians.
In an autograft procedure, bone material is harvested from another part
of the patient's skeleton and grafted to the site of the bone deficit. This
second surgical procedure, harvesting the patient's own bone, increases total
operating time and expense, and can lead to complications such as infection,
chronic pain, deformity and excess blood loss. When an autograft is not
feasible or desirable, allograft bone, obtained from a cadaver, can be used.
While allograft bone is available from numerous bone banks, its use carries the
risks of implant rejection and transmission of infectious agents such as
hepatitis and HIV. Also, allograft bone is not always readily available due to
the storage, processing and donor screening required. In addition, allograft
bone has recently become more costly and less readily available. This may be the
result of regulations governing bone and tissue banks issued in December 1993 by
the FDA because of the risk of transmitting infectious diseases associated with
allograft bone.
The approved indication for Pro Osteon is for the repair of acute
metaphyseal defects in conjunction with rigid internal fixation (plates and
screws) as dictated by the clinical use requirements in skeletally mature
individuals when there is no autogenous bone donor site available. Pro Osteon
is contraindicated (1) for fractures of the growth plate at the end of the bone,
(2) in sites with vascular impairment proximal to the graft site, (3) in the
presence of metabolic or systemic bone disorders, (4) where stabilization of the
fracture is not possible, (5) where soft tissue coverage is not possible, and
(6) in infected wounds. These contraindications, which were specified by the
FDA as part of the approval for Pro Osteon, are generally applicable to the use
of all bone graft materials, rather than to Pro Osteon in particular. The
Company does not believe that these contraindications materially limit the use
of Pro Osteon for its approved indication, or the Company's ability to market
Pro Osteon.
Interpore 200 Porous Hydroxyapatite ("IP200"). The Company produces,
markets and sells IP200 in block and granular form for the following
indications:
Oral Surgery. Loss of substance ("resorption") of the jawbones is a
widespread problem resulting from the extraction of teeth and from gum
disease. In some instances, long-term denture wearing combined with
osteoporosis (loss of bone density and weight) leads to accelerated
resorption of the jawbones. IP200 granules are used to augment the
affected area. The Company received 510(k) clearance for this
indication in September 1982.
Periodontal Defects. Periodontal defects are caused by infection
around the base of the tooth which leads to gum inflammation, infection
of the bone and, finally, destruction of the bone and ligament
surrounding the tooth root. IP200 granules and blocks are used as
fillers for periodontal defects. The Company received 510(k) clearance
for this indication in September 1982.
Craniofacial and Orthognathic Indications. Rebuilding of the facial
skeletal structure from the jawbone to the cranium is often required to
repair defects caused by trauma, cysts, tumors and congenital defects.
These procedures require bone grafts or bone substitutes as onlays or
inlays to the patient's own skeletal structure. IP200 blocks are used
in these applications. The Company received 510(k) clearance to market
IP200 for the craniofacial indication in October 1985 and for the
orthognathic indication in May 1986.
4
5
Orbital Implants. Orbital implants are used to replace damaged or
diseased eyes, to replace existing artificial eyes that have extruded or
migrated and to replace existing artificial eyes to improve tracking and
movement. Since 1989, the Company has manufactured orbital implants for
artificial eyes using its hydroxyapatite material. The Company believes that
these orbital implants provide a superior alternative to other artificial eyes
because the implant is physically attached to the patient's soft tissue.
Because of the attributes of the Company's hydroxyapatite material, the patient
typically experiences integration of the soft tissue into the orbital implant.
The result is improved tracking of the artificial eye with the patient's
companion eye. The Company manufactures this product solely on an OEM basis
under a manufacturing and licensing agreement which expires in 2001.
Other Bone/Soft Tissue Repair Products.
The Company's business strategy for penetrating the bone graft market
includes adding complementary products that relate to the repair of bone and
soft tissue. The Company believes the strategy will enhance sales of its bone
graft materials by providing a broader product base for customer interest and by
providing more compensation potential for its sales representatives. In
September 1995, the Company signed an agreement with an OEM supplier for
exclusive United States distribution of its line of manual arthroscopic
instruments. The Company introduced the product line to the market in January
1996. While the market for arthroscopy products is very competitive, the
Company believes this line offers advantages in product design and quality. The
Company intends to pursue other bone and soft tissue repair products for
addition to its product offering, but there can be no assurance that any such
products will be available to the Company for distribution, licensing or
acquisition.
Dental Implants.
IMZ(R) System. Dental implant devices have gained prominence for use in
the rehabilitation of patients requiring full or partial dentures. Dental
implants are permanent artificial tooth roots anchored in the bone of the upper
or lower jaw. Natural bone attaches to the titanium implant creating a strong
bond. The IMZ dental implant, which is comprised of a titanium cylinder with a
roughened titanium coating, is implanted into the jawbone and extends through
the gums. The IMZ implant contains a shock-absorbing element to which an
artificial tooth or denture piece is secured. Dental implants have the added
benefit of reducing the resorption of the jawbones typically associated with
ordinary denture use.
The IMZ system has been in use since 1978, initially in clinical studies
in the United States and other countries. The American Dental Association
("ADA") first granted acceptance to selected dental implants in 1985 with the
IMZ system gaining provisional acceptance in 1988. Full ADA acceptance for the
IMZ system was received in June 1992 for use in partially or totally edentulous
patients. The Company markets the IMZ system pursuant to 510(k) clearance which
it received in 1986.
Prior to January 1, 1996, the Company's IMZ system was marketed pursuant
to a license agreement which gave the Company an exclusive right to market the
IMZ system. Although the agreement expired on January 1, 1996, the Company has
continued to manufacture and distribute the product under the same general terms
of the expired agreement.
Hex System. To accommodate market demand for a cylinder implant with an
external hex, which provides a means to attach a crown to an implant without
rotation, the Company introduced the Hex Implant System in 1991. This product
is marketed pursuant to 510(k) clearance received by the Company in April 1991.
Threaded System. In 1994, the Company completed a distribution
agreement providing the Company with marketing and sales rights to the Interpore
Threaded Implant System. Sales of this product began in the first quarter of
1995. The Company estimates that threaded implants comprise approximately 60%
of the United States dental implant market.
5
6
Smooth Staple Implant(R) System. In September 1995, the Company entered
into an agreement for exclusive United States distribution rights to the Smooth
Staple Implant System, a titanium implant system designed to aid in the
rehabilitation of patients without teeth in the lower jaw. Implanted from
beneath the jaw, the Smooth Staple can be a more cost effective alternative for
the edentulous (toothless) patient than the use of cylindrical or threaded
implants. Sales of this product began in the fourth quarter of 1995.
IMZ Bone Tack System. In February 1996, the Company introduced the IMZ
Bone Tack System. In May 1996, the Company received a second FDA 510(k)
clearance which permits the Company to market the product for membrane fixation
during bone augmentation procedures in oral/maxillofacial and periodontal
surgery.
Frialit(R) -2 Dental Implant System. In October 1995, the Company
signed an agreement for exclusive United States and Canadian distribution of the
Frialit-2 line of titanium dental implants. Already marketed and sold in Europe
and Asia, the Company believes that the Frialit-2 is the first dental implant
system designed to replace a tooth immediately after a tooth extraction. This
system has enjoyed a significant adoption rate in Germany. The Frialit-2 product
was introduced by the Company in the United States during the third quarter of
1996.
RESEARCH AND DEVELOPMENT
The Company's research and development department consists of eight
full-time employees who conduct research and product development with respect to
biomaterials for bone reconstruction and who provide support for the Company's
dental product development programs. The Company also engages outside
consultants and academic research facilities for assistance with its new product
development. The Company plans to continue to use outside resources for product
research prior to the developmental phase. The Company's engineers also assist
in the design of manufacturing improvements and support validation procedures
for the FDA's requirements for Good Manufacturing Practices ("GMP") and ISO
9001, the quality management system which is a regulatory requirement of the
European Community. The Company's expenditures for research and development
were $2.0 million, $1.9 million and $1.9 million in 1996, 1995 and 1994,
respectively.
Additional Pro Osteon Indications. The Company currently intends to
focus its research and clinical studies on the safety and efficacy of Pro Osteon
as a bone graft material for use in spinal fusion and iliac crest backfill
procedures. In January 1995, the Company received FDA approval of its IDE
application to begin clinical trials for the use of Pro Osteon Implant 200 in
cervical spine interbody fusion procedures. The Pro Osteon will be used in
conjunction with a rigid titanium bone plate to fuse vertebrae in the neck.
This initial FDA approval covers 60 patients at five hospitals in the United
States. In May 1996, the FDA approved the Company's IDE to commence clinical
trials for the use of Pro Osteon Implant 500 to fill the void left by autograft
harvesting procedures in the iliac crest region of a patient's hip. This pilot
study will be performed in conjunction with lumbar spine fusion procedures
involving twenty patients, with ten receiving Pro Osteon as a backfill material,
and ten receiving no backfill material. In the future, the Company may pursue
IDE approval for clinical trials using Pro Osteon as a bone void filler for
other indications. However, the FDA approval process is lengthy and the Company
can give no assurance concerning when or whether it will receive FDA approval to
market Pro Osteon for these or any other indications.
New Hydroxyapatite Products. To enter segments of the bone graft market
not addressed by the Company's current products, the Company must develop new
bone graft materials. In certain cases, physicians may prefer to have the bone
graft substitute material completely replaced over time by the patient's own
bone. Although Pro Osteon and IP200 have some resorptive capability, neither
product is completely replaced over time with the patient's own bone. To
address this need, the Company is developing a resorbable coralline
hydroxyapatite product which is being evaluated in preclinical studies.
6
7
The Company is also investigating the development of an osteoinductive
bone graft material. The Company is studying methods of combining
osteoinductive agents, bioengineered proteins that promote bone growth, with
coralline hydroxyapatite. In an effort to identify an optimal growth factor, the
Company is working with strategic partners to evaluate the use of certain growth
factors with Pro Osteon, and pre-clinical studies have commenced. Also, in 1996
the Company secured rights to a technology that produces a gel-like material
with super-concentrated tissue growth factors derived from the patient's own
blood. The Company is evaluating the use of this material in combination with
Pro Osteon blocks and granules for its ability to promote or accelerate bone
growth into the Pro Osteon material.
CUSTOMERS, SALES AND MARKETING
The decision to use bone graft material is made by the orthopaedic
surgeon. There are approximately 14,000 practicing orthopaedic surgeons in the
United States in private practice, hospitals and orthopaedic treatment centers,
to which the Company directs its marketing efforts for Pro Osteon. The Company
markets Pro Osteon in the United States through a 28-territory direct sales
force and a network of approximately 20 independent dealer organizations, each
employing an average of six to eight sales representatives. The sales
organization is managed by a director of sales and five division managers.
During 1995 and 1996, the Company restructured its distribution channels for the
sale of Pro Osteon. Distribution agreements with certain distributors that were
not achieving satisfactory market penetration were terminated, and direct sales
representatives were recruited and hired for the respective territories. The
Company selects these direct sales representatives and dealer organizations for
their expertise in orthopaedic or medical device sales, their reputation with
the orthopaedic surgeon community and their sales coverage within a geographic
area. Each direct sales representative and dealer organization is given an
exclusive sales territory and is subject to periodic performance reviews and
sales and product training.
Outside of the United States, the Company distributes Pro Osteon through
independent orthopaedic products distributors. In January 1996, the Company
hired three experienced international sales managers who are responsible for
building an organization of independent dealers outside the United States. To
date, the Company has set up distribution arrangements with 34 distributors in
32 countries covering Europe, South America and Asia.
The Company participates in numerous professional meetings including the
American Academy of Orthopaedic Surgeons Meeting, the North American Spine
Society Meeting and the Annual Meeting of the Orthopaedic Trauma Association.
The Company also participates in scientific presentations and professional
seminars at hospitals.
In the United States, the Company markets dental implants and IP200
through its own sales force of nine salespersons to approximately 10,000
customers which include oral surgeons, periodontists, prosthodontists and
general dentists. The Company's customer base also includes major university
teaching hospitals and United States government health care facilities. In
addition to direct selling, the Company promotes these products through trade
journal advertising, attendance at major professional meetings and trade shows,
and by conducting training seminars. The Company employs two dental technical
representatives to provide detailed technical assistance to the Company's
customers. Outside of the United States, IP200 and IMZ are distributed through
more than 50 independent dealers. The Company provides promotional assistance
to foreign dealers through sales brochures, educational materials, educational
seminars and attendance at international professional meetings and trade shows.
For fiscal years 1996 and 1995, the Company's international sales
represented approximately 10% of net sales.
RAW MATERIALS AND MANUFACTURING
Coral is the primary raw material used by the Company in the manufacture
of its coralline hydroxyapatite products. The coral used in the Company's
products is sourced from two genera located in a wide variety of geographic
locations. The Company presently harvests coral in tropical areas of the
Pacific and Indian Oceans. At projected production levels, the amount of coral
imported annually by the Company will amount to less than 1% of the total amount
of coral imported annually into the United States for jewelry and decorative
use.
7
8
Coral is covered under an international treaty entitled "Convention on
International Trade of Endangered Species of Wild Fauna and Flora" ("CITES")
which limits the import/export of raw coral and products derived therefrom in
approximately 140 nations around the world. To date, the limitations imposed by
this treaty have not negatively affected the Company's ability to source raw
coral. While the Company believes that its existing inventory of coral is
sufficient to meet its projected needs for more than one year, there can be no
assurance that the Company will be able to obtain sufficient quantities of
coral in the future, or that it will be able to obtain coral at an acceptable
price.
The manufacturing process for hydroxyapatite materials involves coral
qualification and cutting, hydrothermal conversion, testing, packaging and
sterilization of the product, all of which, with the exception of sterilization,
are performed at the Company's facilities. In the hydrothermal exchange
process, a chemical reaction is initiated whereby the carbonate in the coral is
removed and replaced by phosphate. This results in the coral retaining its
original architecture but becoming a completely different material,
hydroxyapatite.
The Company's dental implant products are supplied by outside vendors in
final packaged form, or as semi-finished components. Following receipt of the
components, the Company inspects, assembles, packages, labels and sterilizes
these components and distributes them as the IMZ system. No assurance can be
given that a continuous supply of dental implant components at competitive
prices will continue to be available to the Company.
COMPETITION
Orthopaedic Bone Graft Substitute Market. The Company's synthetic bone
products compete with natural bone obtained from autograft procedures and
allograft sources and with three other synthetic bone products. Autograft and
allograft bone have been used for graft material for a much longer period of
time than synthetic bone graft materials, and in order to increase its future
sales of Pro Osteon, the Company will have to continue to demonstrate to the
medical community the surgical and patient advantages, safety, efficacy, cost
effectiveness and clinical results of Pro Osteon.
The Company believes that Pro Osteon provides an attractive alternative
to autograft and allograft bone graft materials. In an autograft, a second
surgical procedure is required. Bone material is harvested from another part of
the patient's skeleton and then grafted to the site of the bone deficit. The
harvesting procedure increases total operating time and expense, and can lead to
complications such as infection, excessive blood loss, chronic pain and
deformity. When an autograft is not feasible or desirable, allograft bone,
typically obtained from a cadaver, can be used. To maintain mechanical and
biological properties, some allograft bone is not sterilized. Therefore, unlike
Pro Osteon, which is a sterile and biocompatible material, allograft bone
carries the risks of implant rejection and the transmission of infectious agents
such as hepatitis and HIV. The use of Pro Osteon entails none of these risks,
and provides clinical results comparable to those of autograft material. In
addition, in December 1993 the FDA began regulating allograft processing and
allograft bone tissue, which were previously unregulated.
Grafton(R) is a bone product manufactured by Osteotech, Inc. which
consists of a processed allograft gel available in a variety of forms. Because
it is derived from allograft, Grafton is not regulated as a medical device
under the federal Food, Drug and Cosmetic Act, as amended, and as such, can be
promoted for a wide variety of surgical indications. While the Company believes
that Grafton has many of the same disadvantages as allograft, it is perceived
by some surgeons to have osteoinductive characteristics.
8
9
In May 1993, a second bone graft substitute for orthopaedic applications
was approved by the FDA. This product, Collagraft(R), consists of
hydroxyapatite/tri-calcium phosphate and bovine collagen, which must be mixed
with patients' own bone marrow. The Company believes that this three part
system is more difficult to use due to the mixing process and is more expensive.
In addition, it requires the extraction of bone marrow from the patient's body.
It also requires refrigeration, has a shorter shelf life and raises the risk of
adverse reaction in patients allergic to bovine collagen. This system is
marketed by Zimmer, Inc., a subsidiary of Bristol-Myers Squibb, a competitor
with significantly greater resources and distribution capabilities than the
Company. The manufacturer of this product has received a PMA supplemental
approval from the FDA for a second generation freeze-dried product which is
pre-mixed and requires no refrigeration.
In July 1996, the FDA issued 510(k) clearance to Wright Medical
Technology, Inc. for OsteoSet(TM), a plaster-of-paris bone void filler. There
is very little clinical data available documenting the safety and efficacy of
the product.
Numerous other companies are pursuing additional synthetic bone graft
materials which could ultimately compete with Pro Osteon in the United States.
To the best of the Company's knowledge, none have yet progressed beyond clinical
trials.
Dental Implant Market. The Company competes with many businesses in the
production and distribution of dental implant systems for rehabilitation of
partially and totally edentulous patients. A number of the Company's competitors
have substantially greater resources, larger market share and greater research
and development capabilities than the Company and may, therefore, be expected to
compete aggressively and successfully in the markets for the Company's dental
implant products.
Oral and Maxillofacial Market. IP200 competes with autograft, allograft
and xenograft as well as non-porous hydroxyapatite products for repair or
reconstruction of oral and maxillofacial bone structures. In addition, this
product competes with silicone implants for maxillofacial applications.
Companies selling competitive products sometimes also sell dental implants, so
bundling these products is often a strategy.
The Company competes in all of its markets primarily on the basis of
product performance and price, as well as customer loyalty and service.
GOVERNMENT REGULATION
The Company's products are regulated by the FDA under the federal Food,
Drug and Cosmetic Act, as well as other federal, state and local governmental
authorities and similar regulatory agencies in other countries. The FDA permits
commercial distribution of a new medical device or implant only after the FDA
has accepted for review and cleared a 510(k) premarket notification or has
approved a Premarket Approval application on such medical device or implant. In
general, the FDA will clear marketing of a medical device through the 510(k)
premarket notification process if it is demonstrated that the new product is
substantially equivalent (in terms of safety, efficacy and intended use) to
certain 510(k) cleared products which are already commercially available and
lawfully sold on the market.
The PMA approval process is lengthier and more burdensome than the
510(k) premarket notification process. The PMA process generally requires more
detailed preclinical and clinical studies, as well as manufacturing data and
other information. If clinical studies are required by the FDA, an IDE is also
required. An IDE restricts the use of the device to a limited number of
investigators and patients for clinical studies to demonstrate product safety
and efficacy. An approved PMA application indicates that the FDA has determined
that a device has been proven, through the submission of preclinical and
clinical data and manufacturing and other information, to be safe and effective
for its intended uses.
9
10
The PMA application for Pro Osteon was accepted for filing by the FDA in
February 1988. In October 1992, the Company received approval from the FDA of
its PMA application to market its synthetic bone graft material, Pro Osteon, for
certain acute metaphyseal defects (defects in the wide part of long bones). In
December 1993, the Company received supplemental approval from the FDA to market
Pro Osteon in granular forms and a wide variety of block configurations up to 30
cc's in total volume. The Company's dental implants, IP200 and orbital implants
were approved for marketing through submission to the FDA of the 510(k)
premarket notification.
Manufacturers competing in the United States market promote their dental
implant products (Class III medical devices) pursuant to 510(k) clearance, an
approval to market a device demonstrated to be substantially equivalent to
certain products which were commercially available prior to May 28, 1976. In
1990, Congress enacted the Safe Medical Device Act of 1990 which required the
FDA to either down-classify these Class III devices to Class I or II, or publish
a date for the call for PMA applications for any remaining Class III devices on
the market. The Company expects that within the next year certain dental
implants will be down-classified to Class II, but others will remain as Class
III. There is a possibility that the Company's dental implants will remain
Class III and that a PMA will be required to continue marketing some or all of
the Company's dental implant products. The Company has been collecting clinical
data to support an expected PMA application. The Company can give no assurance
concerning when or whether it would receive a PMA approval from the FDA for its
dental implant products.
Governmental regulation may prevent or substantially delay the marketing
of the Company's proposed products, cause the Company to undertake costly
procedures and furnish a competitive advantage to the more substantially
capitalized companies with which the Company competes. After approval, the FDA
may require post-marketing approval surveillance programs to monitor the effects
of an approved medical device. FDA approval may be withdrawn for noncompliance
with regulatory standards or the occurrence of unforeseen problems following
initial marketing. In addition, the extent of potentially adverse government
regulations which might arise from future administrative action or legislation
cannot be predicted. Finally, product modifications may require the submission
of a new 510(k) notification or PMA supplement and future products may require
PMA approval. There can be no assurance that marketing clearances or approvals
will be obtained on a timely basis or at all. Delays in receiving, or the
failure to receive, such clearances could have a material adverse effect on the
Company.
The Company is also registered as a medical device manufacturer with the
FDA and with state agencies such as the Food and Drug Branch of the California
Department of Health Services (the "California DHS"). The FDA and state
agencies inspect the Company from time to time to determine whether the Company
is in compliance with various regulations relating to medical device
manufacturing, including the FDA's GMP regulations which govern manufacturing,
testing, quality control, and product labeling of medical devices. In addition,
the FDA actively enforces regulations prohibiting the promotion of medical
devices for unapproved indications, which is also prohibited by Company policy.
Material violation of such regulations could lead to the imposition of
injunctions, suspensions or loss of regulatory approvals, refusal to approve
applications for future marketing clearances, product recalls, termination of
distribution, or product seizures and, in the most egregious cases, criminal
sanctions or closure of the Company's manufacturing facility. The Company
believes it is in compliance with the regulations established by the FDA and the
California DHS applicable to its business. The FDA and the California DHS have
inspected the Company's manufacturing facilities and quality assurance
procedures.
The Company must also comply with registration requirements of foreign
governments and with import and export regulations when distributing its
products to foreign nations. Each foreign country's regulatory requirements for
product approval and distribution are unique and may require the expenditure of
substantial time, money and effort to obtain and maintain. In September 1995,
the Company received approval to use the "CE" mark for its entire line of
orthopaedic and oral/maxillofacial synthetic bone graft materials. The CE mark
indicates that the products are approved for sale within 18 countries in the EC
(European Community) and EFTA (European Free Trade Association) and that the
Company is in compliance with the EN/ISO 9001 standards which govern medical
device manufacturers marketing products in Europe. Pro Osteon and IP200 were
both approved for a broad range of grafting applications.
The Company does not anticipate that compliance with federal, state and
local environmental laws will have any material adverse effect on the Company's
business, results of operations or capital expenditures.
10
11
PROPRIETARY RIGHTS
Hydroxyapatite Materials. In September 1976, the Company was granted a
license with respect to five United States patents and related foreign patents
covering the ReplamineformTM technology. The license provides the Company with
exclusive rights to manufacture and distribute the licensed products until
expiration of the patents. The most significant patent concerns the right to
manufacture a hydroxyapatite bone graft substitute material from marine coral,
and it expired in December 1994. The remaining patents expire in 1997. The
Company does not anticipate any significant impact on its business as a result
of the expiration of the ReplamineformTM patents, because it believes the
lengthy FDA approval process and the Company's proprietary manufacturing
processes are more significant barriers to entry than patent protection.
The Company owns five United States patents related to improvements on
the process for manufacturing biomaterials for bone reconstruction: two of the
patents relate to a version of Pro Osteon that is more resorbable, and three of
the patents relate to a non-coral based synthetically produced porous
hydroxyapatite. These patents expire between 2006 and 2013. The Company is
evaluating the feasibility of developing products which call upon the patent
protection provided therein.
Dental Implants. In June 1986, the Company entered into a License and
Consulting Agreement and a Trademark License Agreement (collectively, the "IMZ
License") with a German company owned by Dr. Axel Kirsch, the developer of IMZ.
In return for royalties on the sale of IMZ and certain related products, the IMZ
License gave the Company an exclusive license to manufacture, market and sell
IMZ and related technology, and to use the trademark "IMZ," in North America,
South America, Central America, Australia and New Zealand until January 1, 1996.
Although the agreement expired on January 1, 1996, the Company has continued to
manufacture and distribute the product under the same general terms of the
expired agreement.
Patents and Personnel. As part of its ongoing research, development and
manufacturing activities, the Company has a policy of seeking patent protection.
Patents relating to particular products, uses or procedures, however, do not
preclude other manufacturers from employing alternative processes or from
successfully marketing substitute products. There can be no assurance that any
pending or future patent applications will be granted or that any current or
future patent will provide adequate protection for the Company's technology and
products. There can also be no assurance that others will not independently
develop similar technologies or duplicate any technology developed by the
Company or that the Company's technology will not infringe patents or other
rights owned by others, licenses to which may not be available to the Company or
available on favorable terms. The Company believes that although the patents
often are necessary to protect its technology and products, the lengthy FDA
approval process and certain manufacturing processes are more significant
barriers to entry. Moreover, much of the proprietary technology and
manufacturing processes developed by the Company reside in its key scientific
and technical personnel and such technology and processes are not easily
transferable to other scientific and technical personnel. The loss of the
services of key scientific, technical and manufacturing personnel could have a
material adverse effect on the Company's business and results of operations.
Trademarks. "Pro Osteon", "Interpore" and "Interpore 200" are
registered trademarks of the Company. "IMZ", "Smooth Staple Implant" and
"Frialit" are trademarks of other companies.
EMPLOYEES
As of March 1, 1997, the Company had 117 full-time employees, of whom 60
were engaged in marketing and sales, 22 in manufacturing, 12 in regulatory
affairs and quality assurance, 15 in general administration and finance and 8 in
research and development. None of these employees is represented by a union,
and the Company has never experienced a work stoppage. Management considers its
employee relations to be good.
11
12
ITEM 2. PROPERTIES
The Company leases a 36,800 square foot facility in Irvine, California.
This facility was approved in March 1994 by the FDA for the manufacture of Pro
Osteon. The average annual lease expense over the ten year term of the lease,
which expires January 31, 2003, is $387,000. The lease provides a right to
extend the term for an additional five years at the fair market lease rate of
the facility on the extension date, but not less than the rate paid by the
Company during the month immediately preceding the commencement of the extension
period. The Company also leases two facilities totaling 7,949 square feet to
provide additional warehousing. The Company believes the facilities will be
adequate to serve its operational needs over the next one to two years.
ITEM 3. LEGAL PROCEEDINGS
The Company is subject to an inherent risk of product liability and
other liability claims which may involve significant claims and defense costs.
From time to time, claims have been made against the Company related to the
failure of various components of the IMZ system. Additional claims have been
asserted related to complications from certain uses of IP200 block material,
which uses have not been recommended by the Company since 1987. To date, all
claims against the Company have been covered by insurance policies, except for
deductible limits and self-insured retentions. The Company currently has
primary product liability insurance with coverage limits of $5 million per
occurrence and $5 million in the aggregate per year, and excess product
liability insurance with a coverage limit of $5 million. Product liability
insurance is expensive and in the future may not be available in acceptable
amounts, on acceptable terms, or at all. If the Company were to be held liable
for damages exceeding the limits or outside of the scope of its insurance
coverage, the business and results of operations of the Company could be
materially adversely affected. The Company's reputation and business could be
adversely affected by product liability claims, regardless of their merit or
eventual outcome.
On April 7, 1995, Jonathan J. Kaufman ("Kaufman") filed a claim
(Jonathan J. Kaufman v. Interpore Orthopaedics, Inc. and Exogen, Inc.) in the
United States District Court, Southern District of New York, against Interpore
Orthopaedics, Inc. ("Orthopaedics"), a subsidiary of the Company, and Exogen,
Inc. Kaufman had entered into a consulting agreement with Meditron Corporation,
which in 1989 merged with a corporate predecessor to Orthopaedics. In March
1993, the Company and Orthopaedics sold the operating assets and related
liabilities of Orthopaedics to the corporate predecessor to Exogen. In this
action, Kaufman seeks royalties, pursuant to the consulting agreement, on the
sale of products by Exogen.
In June 1995, the Company answered the complaint, denying any liability
to Kaufman, and, in June 1995, cross-claimed against Exogen for indemnification
and contribution. In March 1996, Interpore and Exogen entered into an agreement
settling their respective cross-claims and counter-cross-claims. The settlement
provides, among other things, that (1) any adverse judgment will be entered
against Exogen and Interpore jointly and severally; and (2) Exogen will
indemnify Interpore for any payments that are required to be made to Kaufman as
a result of this litigation and Exogen and Interpore will resolve separately in
arbitration their respective liabilities, if any. In connection with the
settlement, in April 1996, the court entered an order dismissing Interpore's
cross-claims and Exogen's counter-cross-claims. Fact discovery in the case has
been completed and expert discovery is expected to be completed by the end of
May 1997. The Company, together with Exogen, intends to defend the underlying
action vigorously.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
12
13
PART II
ITEM 5. MARKET FOR REGISTRANTS' COMMON STOCK AND RELATED STOCKHOLDER MATTERS
Since December 20, 1993, the Company's common stock has traded on The
Nasdaq Stock Market under the symbol "BONZ". The table below sets forth the
high and low sale prices for the Company's common stock for the four quarters in
each of 1996 and 1995. Amounts shown represent actual sales transactions as
reported on The Nasdaq Stock Market.
1996 High Low
----- ---- -----
Fourth Quarter $6 $4 1/4
Third Quarter 6 1/8 4 1/4
Second Quarter 9 5
First Quarter 7 4 5/8
1995 High Low
----- ---- -----
Fourth Quarter $5 3/8 $4 3/8
Third Quarter 6 4 7/16
Second Quarter 7 1/4 5
First Quarter 9 6 1/2
On March 20, 1997, the closing sale price for the Company's common
stock as reported on The Nasdaq Stock Market was $5 3/16. The number of record
holders of the Company's common stock as of March 20, 1997 was 341.
The Company currently does not pay any dividends on its preferred and
common stock and its Board of Directors has no present intention to pay cash
dividends. The Board of Directors intends to use any earnings for the
development and expansion of the business.
13
14
ITEM 6. SELECTED FINANCIAL DATA
The selected financial data as of and for the years ended December 31, 1996,
1995, 1994, 1993 and 1992 set forth below have been derived from the
consolidated financial statements of the Company.
YEAR ENDED DECEMBER 31,
---------------------------------------------------------------------
1996 1995 1994 1993 1992
------- -------- ------- -------- -------
(IN THOUSANDS, EXCEPT PER SHARE DATA)
STATEMENT OF OPERATIONS DATA:
Net sales . . . . . . . . . . . . $19,917 $17,103 $18,458 $14,315 $12,386
Cost of goods sold . . . . . . . . 5,394 4,520 5,648 4,898 4,548
Royalty expense . . . . . . . . . . 249 278 761 612 647
------- ------- ------- ------- -------
Gross profit . . . . . . . . . . . 14,274 12,305 12,049 8,805 7,191
Total operating expenses . . . . . 14,379 12,332 10,137 8,246 8,065
------- ------- ------- ------- -------
Income (loss) from operations . . . (105) (27) 1,912 559 (874)
Total interest and other income
(expense), net . . . . . . . . . 763 661 601 (9) (53)
------- ------- ------- ------- -------
Income (loss) before taxes . . . . 658 634 2,513 550 (927)
Provision (credit) for income taxes - (1,404) 101 14 -
------- ------- ------- ------- -------
Net income (loss) . . . . . . . . . $ 658 $ 2,038 $ 2,412 $ 536 $ (927)
====== ======= ======= ====== ======
Net income (loss) per share . . . $ .09 $ .27 $ .32 $ .10 $ (.22)
====== ======= ======= ====== ======
Shares used in computing net income
(loss) per share . . . . . . . . 7,468 7,535 7,568 5,279 4,188
====== ======= ======= ====== ======
YEAR ENDED DECEMBER 31,
---------------------------------------------------------------------
1996 1995 1994 1993 1992
------- -------- ------- -------- -------
(IN THOUSANDS)
BALANCE SHEET DATA:
Total assets . . . . . . . . . . . $ 20,323 $ 21,705 $ 20,177 $ 15,667 $ 5,591
Long-term debt, including current
portion . . . . . . . . . . . . . 5 191 369 712 219
Redeemable preferred stock . . . . - - - - 8,665
Preferred and common stock . . . . 35,917 37,101 37,219 34,963 14,822
Accumulated deficit . . . . . . . . (17,386) (18,044) (20,082) (22,494) (22,429)
14
15
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION
RESULTS OF OPERATIONS
The following table presents the Company's operating results as percentages:
Percentage of Net Sales Percentage Change
------------------------------------- ---------------------
1996 vs. 1995 vs.
Year ended December 31, 1996 1995 1994 1995 1994
- ----------------------- ----- ----- ----- ------- -------
Net sales 100.0% 100.0% 100.0% 16.5% -7.3%
Cost of goods sold 27.1% 26.4% 30.6% 19.3% -20.0%
Royalty expense 1.2% 1.7% 4.1% -10.4% -63.4%
----- ----- ----- ----- -----
Gross profit 71.7% 71.9% 65.3% 16.0% 2.1%
----- ----- ----- ----- -----
Operating expenses:
Research and development 10.1% 11.3% 10.5% 3.2% -.2%
Selling and marketing 49.3% 44.1% 32.2% 30.3% 26.9%
General and administrative 12.8% 14.3% 12.2% 4.7% 8.3%
Provision for distributor
returns .0% 2.4% .0% -100.0% N/A
----- ----- ----- ----- -----
Total operating expense 72.2% 72.1% 54.9% 16.6% 21.7%
----- ----- ----- ----- -----
Income (loss) from operations -.5% -.2% 10.4% N/A N/A
===== ===== ===== ===== =====
1996 Compared to 1995
For the year ended December 31, 1996, net sales of $19.9 million were
$2.8 million or 16.5% higher than sales of $17.1 million for the previous year.
Sales of orthopaedic products, primarily Pro Osteon bone graft
substitute material for orthopaedic applications, increased by $3.7 million or
46.6% to $11.7 million compared to $8.0 million for the year ended December 31,
1995. During 1995, the Company began to restructure its distribution channels
for the sale of Pro Osteon. Distribution agreements with certain domestic
distributors that were not achieving satisfactory market penetration were
terminated, and direct sales representatives were recruited and hired for the
respective territories. In the first quarter of 1996, the Company continued its
restructuring of domestic distribution channels and established an international
sales management group. In 1996, Pro Osteon sales through domestic direct sales
representatives increased by 146% over 1995, and sales of Pro Osteon to
international distributors increased 181% over 1995. These increases were
partially offset by a 5.1% decrease in sales to domestic distributors.
Sales of the Company's OEM products, which consist mostly of porous
hydroxyapatite material for orbital implants manufactured for a single customer,
increased by 3.9% to $1.11 million for the year ended December 31, 1996 versus
$1.07 million for the prior year.
Sales of the Company's oral/maxillofacial products (titanium dental
implant systems and Interpore 200 Porous Hydroxyapatite for dental use) declined
by $934,000 or 11.6% from $8.1 million in 1995 to $7.1 million in 1996.
Continued strong competition in this slow growth market along with an absence of
the introduction of major new dental product lines have contributed to this
decline. In September 1996, the Company signed a letter of intent to sell its
dental business to Friatec AG of Mannheim, Germany. Since the transaction was
not completed by the deadline provided for in the letter of intent, the period
of exclusivity expired. In January 1997, the Company signed a letter of intent
to sell the dental business to Steri-Oss, Inc. of Yorba Linda, California.
Consummation of the transaction is contingent upon certain conditions including
satisfactory completion of due diligence, negotiation of a mutually acceptable
definitive agreement, and the approvals of the boards of directors of the two
companies.
For the years ended December 31, 1996 and 1995, gross margins were 71.7%
and 71.9% of sales, respectively.
15
16
Total operating expenses for the year ended December 31, 1996 increased
by 16.6% or $2.0 million as compared to the same twelve month period of 1995.
Research and development expenses increased by 3.2% but declined as a percentage
of sales from 11.3% in 1995 to 10.1% in 1996. The $2.3 million or 30.3%
increase in selling and marketing expenses from $7.5 million in 1995 to $9.8
million in 1996 primarily related to costs associated with the Company's
expanded orthopaedic direct sales force and the orthopaedic international sales
management group. General and administrative expenses increased $114,000 or
4.7% but decreased as a percentage of sales to 12.8% in 1996 from 14.3% in 1995.
Operating expenses for 1995 included a $411,000 provision for distributor
returns to reflect the estimated value of product returns the Company would
accept from distributors terminated as of December 31, 1995.
The decrease of $116,000 in interest income relates to lower average
combined cash, cash equivalents and short-term investments primarily resulting
from the Company's $1.3 million repurchase of its common stock in 1996. Other
income increased $201,000, primarily the result of royalty payments earned on
sales of a product line which the Company sold in 1993.
No provision for income taxes was recorded in 1996, as a result of the
Company's utilization of net operating loss carryforwards. The credit for
income taxes in 1995 of $1.4 million reflects recognition of $1.5 million of
deferred tax assets, primarily consisting of net operating loss carryforwards,
which had previously been fully reserved in accordance with Statement of
Financial Accounting Standards No. 109, Accounting for Income Taxes.
1995 Compared to 1994
For the year ended December 31, 1995, net sales totaled $17.1 million.
This represented a decrease of $1.4 million or 7.3% versus the previous year's
net sales of $18.5 million.
Sales of orthopaedic products improved 2.5% from $7.8 million in 1994 to
$8.0 million in 1995. Sales to distributors declined by $2.1 million due to the
termination of distributor agreements and short-term uncertainties caused by the
restructuring of the Company's distribution channels for the sale of Pro Osteon,
and reduced sales orders to distributors with high levels of inventory.
Offsetting the decline in sales to distributors was an increase in sales by
direct representatives.
Sales of the Company's OEM products increased from $900,000 to $1
million from 1994 to 1995.
Sales of oral/maxillofacial products decreased by $1.7 million or 17%
from $9.8 million in 1994 to $8.1 million in 1995. Continued strong competition
in this slow growth market along with the lack of major new dental product
introductions by the Company contributed to the decline.
Gross profit increased by $256,000 over the prior year, and as a
percentage of sales, the gross margin for 1995 was 71.9% versus 65.3% for 1994.
The improvement was caused by an increase in productivity, cost reduction
initiatives, the increased percentage of total sales represented by the higher
margin Pro Osteon and the expiration of royalties previously paid by the Company
on sales of hydroxyapatite products.
Total operating expenses increased in 1995 by 21.7% or $2.2 million
compared to 1994 and as a percentage of sales increased to 72.1% from 54.9%.
Research and development expenses were just over $1.9 million for both periods.
The expansion of the Company's direct orthopaedic sales force was the primary
cause for the 26.9% or $1.6 million increase in selling and marketing expenses
from $5.9 million in 1994 to $7.5 million in 1995. Also, the Company recorded a
$411,000 provision for distributor returns in 1995 to reflect the estimated
value of product returns the Company would accept from certain terminated
distributors in 1996. General and administrative expenses increased $188,000
primarily related to an increase in professional fees.
16
17
The $211,000 increase in interest income in 1995 resulted from higher
interest rates on the Company's interest-bearing deposits. Other income
decreased by $173,000, as 1994 included $210,000 in payments related to the 1993
sale of the assets of Interpore Orthopaedics' ultrasound fracture healing device
business.
The credit for income taxes in 1995 of $1.4 million reflects recognition
of $1.5 million of deferred tax assets, primarily consisting of net operating
loss carryforwards, which had previously been fully reserved in accordance with
Statement of Financial Accounting Standards No. 109, Accounting for Income
Taxes. Management believes that it is more likely than not that these tax
benefits will be realized.
LIQUIDITY AND CAPITAL RESOURCES
At December 31, 1996, cash, cash equivalents and short-term investments
totaled $10.3 million as compared to $11.6 million at the end of 1995. Total
working capital decreased from $17.5 million to $16.9 million and the current
ratio improved from 7.8 to 10.4 at December 31, 1995 and 1996, respectively.
The decrease in cash, cash equivalents and short-term investments of $1.3
million reflects expenditures made for the Company's repurchase of its common
stock during the year.
The Company's $10.3 million total of cash, cash equivalents and
short-term investments remains available to support the Company's continued
investment in the development of its business, including the pursuit of FDA
approvals for additional indications for the use of Pro Osteon, development or
acquisition of new bone graft products or complementary products, and possible
acquisitions of businesses. Additionally, the Company has a $5 million
revolving line of credit which expires in July 1997 and which had no amount
outstanding at December 31, 1996.
At December 31, 1996, there were no material commitments for capital
expenditures.
The Company believes it currently possesses sufficient resources to meet
the cash requirements of its operations for at least the next year.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The Financial Statements and Supplementary Data of the Company are
listed and included under Item 14 of this report.
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
17
18
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
There is hereby incorporated herein by reference the information
appearing under the caption "Proposal 1 - Election of Directors" and under the
caption "Executive Officers of the Company" of the registrant's definitive Proxy
Statement for its 1997 Annual Meeting to be filed with the Securities and
Exchange Commission on or before April 30, 1997.
ITEM 11. EXECUTIVE COMPENSATION
There is hereby incorporated herein by reference the information
appearing under the caption "Executive Compensation" of the registrant's
definitive Proxy Statement for its 1997 Annual Meeting to be filed with the
Securities and Exchange Commission on or before April 30, 1997.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
There is hereby incorporated herein by reference the information
appearing under the caption "Voting Securities and Principal Holders Thereof" of
the registrant's definitive Proxy Statement for its 1997 Annual Meeting to be
filed with the Securities and Exchange Commission prior to April 30, 1997.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
There is hereby incorporated herein by reference the information
appearing under the caption "Certain Relationships and Transactions" of the
registrant's definitive Proxy Statement for its 1997 Annual Meeting to be filed
with the Securities and Exchange Commission prior to April 30, 1997.
18
19
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) (1) The following financial statements are referenced in Part II
Item 8 and submitted herewith:
Page Number
-----------
Report of Independent Auditors F-1
Consolidated Balance Sheets at December 31, 1996 and 1995 F-2
Consolidated Statements of Income for the Years Ended
December 31, 1996, 1995 and 1994 F-3
Consolidated Statements of Shareholders' Equity for the Years
Ended December 31, 1996, 1995 and 1994 F-4
Consolidated Statements of Cash Flows for the Years Ended
December 31, 1996, 1995 and 1994 F-5
Notes to Consolidated Financial Statements F-6
(2) The following financial statement schedule for the years ended
1996, 1995 and 1994 is submitted herewith:
Schedule II - Valuation and Qualifying Accounts
All other schedules are omitted because they are not applicable
or the required information is presented in the financial
statements or notes thereto.
(3) The list of exhibits contained in the Index to Exhibits is
submitted herewith.
(b) No reports on Form 8-K were filed during the fourth quarter of 1996.
19
20
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
INTERPORE INTERNATIONAL
By: /s/ DAVID C. MERCER
-----------------------------
David C. Mercer
President and Chief Executive
Officer
Date: March 20, 1997
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.
TITLE DATE
----- ----
/s/ DAVID C. MERCER President, Chief Executive March 20, 1997
------------------------------------------- Officer and Director
David C. Mercer (Principal Executive Officer)
/s/ RICHARD L. HARRISON Vice President - Finance, March 20, 1997
------------------------------------------- Chief Financial Officer and
Richard L. Harrison Secretary (Principal
Financial and Accounting
Officer)
/s/ GEORGE W. SMYTH, JR. Chairman of the Board March 20, 1997
-------------------------------------------
George W. Smyth, Jr.
/s/ WILLIAM A. EISENECHER Director March 20, 1997
-------------------------------------------
William A. Eisenecher
/s/ G. BRADFORD JONES Director March 20, 1997
-------------------------------------------
G. Bradford Jones
/s/ GUY P. NOHRA Director March 20, 1997
-------------------------------------------
Guy P. Nohra
20
21
REPORT OF INDEPENDENT AUDITORS
The Board of Directors
Interpore International
We have audited the accompanying consolidated balance sheets of Interpore
International as of December 31, 1996 and 1995, and the related consolidated
statements of income, shareholders' equity and cash flows for each of the three
years in the period ended December 31, 1996. Our audits also included the
financial statement schedule listed in the Index at Item 14(a). These financial
statements and schedule are the responsibility of the Company's management.
Our responsibility is to express an opinion on these financial statements and
schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the consolidated financial position of Interpore
International at December 31, 1996 and 1995, and the consolidated results of
its operations and its cash flows for each of the three years in the period
ended December 31, 1996, in conformity with generally accepted accounting
principles. Also, in our opinion, the related financial statement schedule,
when considered in relation to the basic financial statements taken as a whole,
presents fairly in all material respects the information set forth therein.
ERNST & YOUNG LLP
Orange County, California
February 7, 1997
F-1
22
Interpore International
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARE DATA)
DECEMBER 31,
---------------------------
1996 1995
---------- ---------
ASSETS
Current assets:
Cash and cash equivalents $ 6,112 $ 3,694
Short-term investments 4,220 7,935
Accounts receivable, less allowance for doubtful accounts of
$339 and $523 in 1996 and 1995, respectively 3,771 3,175
Inventories 3,462 3,757
Prepaid expenses 436 480
Deferred income taxes 596 596
Other current assets 107 438
-------- --------
Total current assets 18,704 20,075
Property, plant and equipment, net 688 699
Deferred income taxes 904 904
Other assets 27 27
-------- --------
Total assets $ 20,323 $ 21,705
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 629 $ 860
Accrued compensation and related expenses 591 374
Accrued sales taxes 252 374
Accrued distributor returns - 411
Deferred rent payable 103 151
Other accrued liabilities 212 287
Current portion of long-term debt 5 113
-------- --------
Total current liabilities 1,792 2,570
-------- --------
Long-term debt - 78
Commitments and contingencies
Shareholders' equity:
Series E convertible preferred stock, voting, no par value:
Authorized, issued and outstanding shares - 76,593 at December 31,
1996 and 240,505 at December 31, 1995; aggregate liquidation value of
$574 at December 31, 1996 and $1,804 at December 31, 1995 484 1,520
Preferred stock:
Authorized shares - 296,358; issued and outstanding shares - none - -
Common stock, no par value:
Authorized shares - 20,000,000; issued and outstanding shares -
6,945,447 at December 31, 1996 and 6,958,642 at December 31, 1995 35,433 35,581
Accumulated deficit (17,386) (18,044)
-------- --------
Total shareholders' equity 18,531 19,057
-------- --------
Total liabilities and shareholders' equity $ 20,323 $ 21,705
======== ========
See accompanying notes.
F-2
23
Interpore International
CONSOLIDATED STATEMENTS OF INCOME
(IN THOUSANDS, EXCEPT PER SHARE DATA)
YEAR ENDED DECEMBER 31,
------------------------------------------
1996 1995 1994
------- ------- -------
Net sales $19,917 $17,103 $18,458
Cost of goods sold 5,394 4,520 5,648
Royalty expense 249 278 761
------- ------- -------
Gross profit 14,274 12,305 12,049
------- ------- -------
Operating expenses:
Research and development 2,001 1,939 1,942
Selling and marketing 9,826 7,544 5,945
General and administrative 2,552 2,438 2,250
Provision for distributor returns - 411 -
------- ------- -------
Total operating expenses 14,379 12,332 10,137
------- ------- -------
Income (loss) from operations (105) (27) 1,912
------- ------- -------
Interest income 553 669 458
Interest expense (28) (45) (67)
Other income 238 37 210
------- ------- -------
Total interest and other income, net 763 661 601
------- ------- -------
Income before taxes 658 634 2,513
Provision (credit) for income taxes - (1,404) 101
------- ------- -------
Net income $ 658 $ 2,038 $ 2,412
======= ======= =======
Net income per share $ .09 $ .27 $ .32
======= ======= =======
Shares used in computing net income per share 7,468 7,535 7,568
======= ======= =======
See accompanying notes.
F-3
24
Interpore International
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(IN THOUSANDS)
Series E Convertible
Peferred Stock Common Stock
-------------------- ------------------- Accumulated
Shares Amount Shares Amount Deficit
------ ------- ------ ------ -----------
Balance at December 31, 1993 594 $3,754 6,196 $31,209 $(22,494)
Exercise of stock options - - 83 108 -
Conversion of preferred stock
into common stock (80) (508) 81 508 -
Exercise of underwriters' over-
allotment option - - 330 2,148 -
Net income - - - - 2,412
---- ------- ----- ------- --------
Balance at December 31, 1994 514 3,246 6,690 33,973 (20,082)
Exercise of stock options - - 31 74 -
Conversion of preferred stock
into common stock (273) (1,726) 275 1,726 -
Issuances under employee stock
purchase plan - - 7 36 -
Repurchase of common stock - - (44) (228) -
Net income - - - - 2,038
---- ------- ----- ------- --------
Balance at December 31, 1995 241 1,520 6,959 35,581 (18,044)
Exercise of stock options - - 51 75 -
Conversion of preferred stock
into common stock (164) (1,036) 164 1,036 -
Issuances under employee stock
purchase plan - - 12 64 -
Repurchase of common stock - - (241) (1,323) -
Net income - - - - 658
---- ------- ----- ------- --------
Balance at December 31, 1996 77 $ 484 6,945 $35,433 $(17,386)
==== ======= ===== ======= ========
See accompanying notes.
F-4
25
INTERPORE INTERNATIONAL
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
YEAR ENDED DECEMBER 31,
-----------------------------------------
1996 1995 1994
-------- -------- ---------
OPERATING ACTIVITIES
Net income $ 658 $ 2,038 $ 2,412
Adjustments to reconcile net income to net cash provided by
(used in) operating activities:
Depreciation and amortization 371 323 301
Changes in operating assets and liabilities:
Accounts receivable (596) 902 (1,965)
Inventories 295 (1,512) (542)
Prepaid expenses 44 (232) (44)
Other assets 331 (26) (70)
Deferred income taxes - (1,500) -
Accounts payable (231) (174) 467
Accrued liabilities (439) (40) (282)
------- ------- -------
Net cash provided by (used in) operating activities 433 (221) 277
------- ------- -------
INVESTING ACTIVITIES
Purchases of short-term investments, net 3,715 (1,979) (5,956)
Capital expenditures (360) (220) (411)
------- ------- -------
Net cash provided by (used in) investing activities 3,355 (2,199) (6,367)
------- ------- -------
FINANCING ACTIVITIES
Repurchase of common stock (1,323) (228) -
Proceeds from exercise of stock options 75 74 108
Proceeds from employee stock purchase plan 64 36 -
Proceeds from issuance of common stock - - 2,148
Repayments of notes payable - (79) (298)
Repayment of lease financing (186) (99) (87)
------- ------- -------
Net cash provided by (used in) financing activities (1,370) (296) 1,871
------- ------- -------
Net increase (decrease) in cash and cash equivalents 2,418 (2,716) (4,219)
Cash and cash equivalents at beginning of year 3,694 6,410 10,629
------- ------- -------
Cash and cash equivalents at end of year $ 6,112 $ 3,694 $ 6,410
======= ======= =======
See accompanying notes.
F-5
26
Interpore International
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
ORGANIZATION AND DESCRIPTION OF BUSINESS
Interpore International (the "Company") is a biomaterials company that
develops, manufactures and markets synthetic bone graft materials for the
orthopaedic, oral and maxillofacial markets. The Company distributes these
products in the United States and internationally. The Company also
distributes manual arthroscopy instruments and titanium dental implant systems
in the United States and internationally.
BASIS OF PRESENTATION
The accompanying consolidated financial statements include the accounts of the
Company and its subsidiaries, Interpore Orthopaedics, Inc. ("Orthopaedics")
and Interpore Dental, Inc. ("Dental"), after elimination of all significant
intercompany transactions. Certain amounts have been reclassified to conform
to the 1996 presentation.
REVENUE RECOGNITION
Revenue from product sales is recognized at the time of shipment. Provision is
made currently for estimated product returns based on historical experience and
other known factors.
PER SHARE INFORMATION
The calculations of net income per share are based on the weighted average
number of common shares and common share equivalents outstanding during the
periods presented. Common share equivalents result from the dilutive effect,
if any, of outstanding options to purchase common stock.
CONCENTRATIONS OF BUSINESS AND CREDIT RISK
The Company operates in markets which are subject to rapid technological
advancement and significant government regulation. The introduction of
technologically advanced products by competitors and increased regulatory
barriers could have a material impact on the future operations of the Company.
In the normal course of business, the Company provides credit to its customers.
At December 31, 1996, 81% of the Company's accounts receivable are from
domestic customers, and 19% are from foreign customers. The Company performs
ongoing credit evaluations of its customers and maintains allowances for
potential credit losses which, when realized, have been within the range of
management's expectations. As of December 31, 1996, the Company had no
significant concentrations of credit risk. Sales to domestic customers were
90%, 90% and 92% of total sales in 1996, 1995 and 1994, respectively, and sales
to foreign customers were 10%, 10% and 8% of total sales in 1996, 1995 and
1994, respectively. All sales to foreign customers for the periods presented
were denominated in United States dollars.
F-6
27
SHORT-TERM INVESTMENTS
The Company invests excess cash in United States Treasury securities and high
grade corporate marketable securities. Highly liquid investments with a
maturity of three months or less are classified as cash equivalents.
Short-term investments consist of highly liquid investments with a maturity of
more than three months when purchased. Pursuant to Statement of Financial
Accounting Standards No. 115, Accounting for Certain Investments in Debt and
Equity Securities, the Company's short-term investments are classified as
available-for-sale securities and are reported at fair market value. At
December 31, 1996, there were no material unrealized gains or losses on the
short-term investments. All of the Company's short-term investments at
December 31, 1996 mature within twelve months, with the exception of $1.0
million which matures in February 1998.
INVENTORIES
Inventories are stated at the lower of average cost or market. Inventories are
comprised of the following (in thousands):
1996 1995
------ ------
Raw material $ 692 $ 854
Work-in-process 385 523
Finished goods 2,385 2,380
------ ------
$3,462 $3,757
====== ======
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are comprised of the following (in thousands):
1996 1995
------- -------
Machinery and equipment $ 2,143 $ 1,924
Furniture and fixtures 469 351
Tooling 116 101
Leasehold improvements 114 106
------ ------
Property, plant and equipment, at cost 2,842 2,482
Less accumulated depreciation and amortization (2,154) (1,783)
------- -------
Property, plant and equipment, net $ 688 $ 699
======= =======
DEPRECIATION AND AMORTIZATION
Depreciation and amortization are provided using the straight-line method over
the following estimated useful lives:
Machinery and equipment 3 to 5 years
Furniture and fixtures 5 years
Tooling 3 years
Leasehold improvements Lesser of estimated useful life or term of lease
PROVISION FOR DISTRIBUTOR RETURNS
In 1995, the Company commenced a significant restructuring of its distribution
channels for the sale of the Company's synthetic bone graft materials. As of
December 31, 1995, certain distributors had been notified of the termination of
their distribution agreements with the Company. A $411,000 provision was
recorded in 1995 to reflect the estimated value of product returns the Company
accepted from these terminated distributors in 1996.
F-7
28
CONSOLIDATED STATEMENTS OF CASH FLOWS
The Company paid income taxes of $62,000, $128,000 and $26,000 and interest of
$28,000, $45,000 and $67,000 in 1996, 1995 and 1994, respectively. Additions
to obligations under capital leases were $42,000 in 1994.
USE OF ESTIMATES
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the amounts reported in the consolidated financial statements and
accompanying notes. Actual results could differ from those estimates.
2. DEBT
Long-term debt is comprised of the following (in thousands):
1996 1995
---- -----
Equipment lease line $ 5 $ 191
Less current portion (5) (113)
--- -----
$ - $ 78
=== =====
The net book value of assets under the lease line were $4,000 and $166,000 at
December 31, 1996 and 1995, respectively.
The Company has available a $5 million line of credit facility with its primary
bank. The line is secured by substantially all of the assets of the Company
and Orthopaedics, bears interest at the bank's prime rate (8.25% at December
31, 1996), and matures July 5, 1997. The facility contains certain financial
covenants with which the Company was in compliance at December 31, 1996. No
amount was outstanding under the facility at December 31, 1996.
3. SHAREHOLDERS' EQUITY
INITIAL PUBLIC OFFERING
In October 1993, the Board of Directors increased the number of authorized
common shares with no par value to 20 million shares and authorized 296,358
shares of preferred stock, no par value.
In December 1993, the Company completed an initial public offering of 1,760,000
shares of its common stock at a price of $7.00 per share. The net proceeds
raised by the Company were approximately $10.9 million. In January 1994, the
Company sold an additional 330,000 shares of its common stock for net proceeds
of approximately $2.1 million upon the exercise of the underwriters'
over-allotment option granted in connection with the Company's initial public
offering.
F-8
29
SERIES E CONVERTIBLE PREFERRED STOCK
The terms of the Series E Convertible Preferred Stock provide for noncumulative
dividends to be paid at the times and in the amounts paid per share on the
common stock and a liquidation preference at an amount no greater than $7.50
per share. The Series E Convertible Preferred Stock has no redemption rights
(although the Company may redeem the stock in certain circumstances) and is
convertible into common stock at conversion ratios averaging 1.005 shares of
common stock for each share of preferred stock, subject to certain antidilution
provisions. In addition, the Series E Convertible Preferred Stock will
automatically convert into common stock at such time as the closing sale price
of the Company's common stock as reported on The Nasdaq Stock Market has been
at least $10.00 per share for at least 20 out of 30 consecutive trading days.
STOCK OPTIONS
The Company's Amended and Restated Stock Option Plan (the "Amended Plan") and
the 1995 Stock Option Plan (the "1995 Plan") provide for the granting of
incentive and non-qualified stock options to directors, officers, consultants
and key employees to purchase shares of its common stock. The Company's Stock
Option Plan for Non-Employee Directors (the "Directors Plan"), adopted May 25,
1995, provides for automatic grants of non-qualified stock options to
non-employee directors at set times in set amounts. The minimum exercise price
for options granted under all plans is the fair market value of the Company's
common stock on the date of grant. The options generally vest annually over a
four-year period commencing on the first anniversary of the date of grant. The
options typically expire after 10 years.
The Amended Plan provides for up to 1,211,049 shares to be issued pursuant to
options granted under the plan. At December 31, 1995, the Amended Plan was
terminated with respect to all future option grants.
The 1995 Plan provides for a maximum of 1.5 million shares to be issued
pursuant to options granted under the plan. The number of shares reserved for
issuance under this plan increases annually by an amount equal to 3% of the
number of shares of common stock issued and outstanding as of the close of
business on December 31 of the immediately preceding year, up to the plan
maximum of 1.5 million shares. The maximum number of shares which may be
issued pursuant to options granted during 1997 is approximately 239,000.
The Directors Plan provides for a maximum of 200,000 shares to be issued
pursuant to options granted under the plan. At December 31, 1996, there were
approximately 141,000 shares available for grant under the Directors Plan.
The following is a summary of stock option activity for the periods indicated:
1996 1995 1994
--------------- --------------- ------------
Options outstanding at beginning of year 1,202,857 959,917 581,947
Options granted during the year 261,000 290,750 547,850
Options exercised during the year (51,215) (31,289) (82,525)
Options forfeited during the year (9,515) (16,521) (87,355)
-------------- -------------- -------------
Options outstanding at end of year 1,403,127 1,202,857 959,917
============== ============== =============
Exercise price of options outstanding at
end of the period $1.00 to $9.00 $1.00 to $9.00 $.30 to $9.00
============== ============== =============
Exercise price of options exercised
during the period $1.00 to $2.50 $ .30 to $2.50 $.25 to $5.00
============== ============== =============
Options exercisable at end of year 695,911 456,663 256,628
============== ============== =============
F-9
30
The weighted average exercise price per share for each stock option activity
and the estimated fair value per share of options granted for the periods
indicated follows:
1996 1995
----- -----
Weighted average exercise price per share of:
Options outstanding at beginning of year $5.07 $4.74
Options granted during the year 5.32 5.92
Options exercised during the year 1.46 2.19
Options forfeited during the year 5.47 6.08
Options outstanding at end of year 5.24 5.07
Estimated fair value per share of options
granted during the year 2.73 3.04
The weighted average remaining contractual life of stock options outstanding at
December 31, 1996 and 1995 were approximately 7.4 and 7.9 years, respectively.
EMPLOYEE STOCK PURCHASE PLAN
In June 1994, the Company's shareholders approved the adoption of a qualified
employee stock purchase plan which allows employees to purchase shares of the
Company's common stock every six months through payroll deductions. The
purchase price for the shares is 85% of the lesser of the fair market value of
such shares on the first or last day of each six-month period. The plan
provides for a maximum of 100,000 shares to be issued pursuant to the plan. As
of December 31, 1996, 19,538 shares of common stock had been issued pursuant to
the plan.
SHAREHOLDER RIGHTS PLAN
Effective August 1995, the Company's Board of Directors adopted a Shareholder
Rights Plan. Every share of the Company's common stock currently issued or to
be issued is accompanied by one right, and every common share issued upon
conversion of the Company's preferred stock also will be accompanied by one
right. The plan provides for the rights to become exercisable upon the earlier
to occur of (i) ten days following the announcement that a person or group of
persons has acquired or obtained the right to acquire 20% or more of the
Company's common stock, or (ii) ten days following the announcement or
commencement of a tender offer which would result in ownership of 20% or more
of the common stock.
If any person or group of persons acquires 20% or more of the Company's common
stock, each right, once exercisable and excluding any rights acquired by the
20% holder, will entitle its holder to purchase that number of additional
shares of the Company's common stock having a market value of twice the rights'
exercise price. If the Company is involved in a merger or other business
combination involving the exchange of the Company's common stock for stock of
an acquiring company at any time after the rights become exercisable, each
right will entitle its holder to purchase that number of the acquiring
company's common stock having a market value of twice the rights' exercise
price.
The rights' current exercise price is $33.00. The exercise price and the
number of shares issuable upon exercise are subject to adjustment from time to
time to prevent dilution. The rights will expire on August 28, 2005, subject
to the Company's right to extend such date, unless earlier redeemed or
exchanged by the Company or terminated. The Company is entitled to redeem the
rights at one cent per right at any time before they become exercisable.
F-10
31
ACCOUNTING FOR STOCK-BASED COMPENSATION
The Company applies Accounting Principles Board Opinion No. 25 (APB 25),
Accounting for Stock Issued to Employees and related interpretations in
accounting for its employee stock options because, as discussed below, the
alternative fair value accounting provided for under Statement of Financial
Accounting Standards No. 123 (SFAS 123), Accounting for Stock-Based
Compensation, requires use of option valuation models that were not developed
for use in valuing employee stock options. Under APB 25, because the exercise
price of the Company's employee stock options equals the market price of the
underlying stock on the date of grant, no compensation expense is recognized.
Pro forma information regarding net income and earnings per share is required
by SFAS 123, and has been determined as if the Company had accounted for
employee stock options granted on or after January 1, 1995 under the fair value
method of SFAS 123. The fair value for these options was estimated at the date
of grant using the Black-Scholes option pricing model with the following
weighted average assumptions: a risk free interest rate of 6%, a volatility
factor of the expected market price of the Company's common stock of .51, a
weighted-average expected life of the option of five years and no dividend
yield.
For purposes of pro forma disclosures, the estimated fair value of the options
is amortized to expense over the options' vesting periods. The Company's pro
forma information, which reflects the charges related to options issued in 1996
and 1995 and may not be indicative of such charges in future periods, is as
follows:
1996 1995
---- ------
Pro forma net income (in thousands) $328 $1,911
Pro forma net income per share $.04 $ .25
4. INCOME TAXES
The Company uses the liability method of accounting for income taxes as set
forth in Statement of Financial Accounting Standards No. 109, Accounting for
Income Taxes. Under this method, deferred taxes are determined based on the
difference between the financial statement and tax bases of assets and
liabilities using enacted tax rates in effect in the years in which the
differences are expected to reverse. Deferred tax assets are recognized and
measured based on the likelihood of realization of the related tax benefit in
the future.
A reconciliation of the provision (credit) for income taxes using the federal
statutory rate to the book provision for income taxes follows (in thousands):
1996 1995 1994
---- ------- -------
Statutory federal provision for income taxes $ 224 $ 216 $ 880
Increase (decrease) in taxes resulting from:
Realization of loss carryforwards (224) (216) (880)
Federal alternative minimum tax - 58 70
State tax, net of federal benefit - 38 31
Reduction in valuation allowance - (1,500) -
----- ------- ----
$ - $(1,404) $101
===== ======= ====
F-11
32
Significant components of the provision (credit) for income taxes are as
follows (in thousands):
1996 1995
---- -------
Current expense:
Federal $ - $ 58
State - 38
--- -------
Total current - 96
--- -------
Deferred credit:
Federal - (1,275)
State - (225)
--- -------
Total deferred - (1,500)
--- -------
$ - $(1,404)
=== =======
At December 31, 1996, the Company has unused net operating loss carryforwards
of approximately $8.6 million for federal income tax purposes which expire
beginning in 2001. The Company also has federal and California research and
development tax credit and alternative minimum tax credit carryforwards of
approximately $245,000 and $120,000, respectively. The research and
development tax credit began to expire in 1996. Prior to 1995, a valuation
allowance was recorded to entirely offset the tax benefits of these
carryforwards. In 1995, the valuation allowance was reduced to recognize the
future tax benefits which management believes are more likely than not to be
realized.
The Tax Reform Act of 1986 includes provisions which significantly limit the
potential use of net operating losses and tax credit carryforwards in
situations where there is a change in ownership, as defined, of more than 50%
during a cumulative three-year period. Accordingly, if a change in ownership
occurs, the ultimate benefit realized from these carryforwards may be
significantly reduced in total, and the amount that may be utilized in any
given year may be significantly limited. California has enacted similar
legislation. The Company has had stock issuances during the past three years;
however, these issuances did not cause a greater than 50% change in ownership
at December 31, 1996.
In addition to the net operating losses discussed above, the Company has net
operating loss carryforwards and research and development tax credit
carryforwards at December 31, 1996 of approximately $7.4 million and $55,000,
respectively, for federal income tax purposes resulting from the acquisition of
Orthopaedics. As a result of the acquisition, Orthopaedics experienced a more
than 50% ownership change. Accordingly, under the provisions of the 1986 Tax
Reform Act, the use of Orthopaedics' net operating loss carryforwards is
limited to approximately $300,000 per year. These carryforwards expire
beginning in the year 2001. As a result of the annual limitation, it is
estimated that a maximum of $3.9 million in net operating loss carryforwards
will be available for use prior to expiration. The ultimate realization of the
benefits of these loss and credit carryforwards is dependent on future
profitable operations of Orthopaedics.
F-12
33
Deferred income taxes reflect the net tax effects of temporary differences
between the carrying amounts of assets and liabilities for financial reporting
purposes and the amounts used for income tax purposes. The components of the
net deferred tax asset at December 31, 1996 and 1995 consist of the following
(in thousands):
1996 1995
-------- --------
Interpore net operating loss carryforwards $ 2,935 $ 2,887
Orthopaedics net operating loss carryforwards 1,317 1,530
Research and development and alternative minimum tax
credit carryforwards 363 351
Orthopaedics research and development tax credit carryforward 19 19
Reserves and accruals not currently deductible for tax purposes 387 608
Inventory capitalization 270 136
Depreciation not currently deductible for tax purposes 58 59
------- -------
Total deferred tax assets 5,349 5,590
Less valuation allowance (3,849) (4,090)
------- -------
Net deferred tax asset $ 1,500 $ 1,500
======= =======
5. COMMITMENTS AND CONTINGENCIES
LICENSE AGREEMENTS
The Company paid royalties ranging from 1% to 8% of net sales of certain of its
dental products. Rights to sell the products had been licensed to the Company
under an agreement with a patent right holder that expired on January 1, 1996.
The parties to the agreement have been operating under substantially similar
terms as those set out in the original agreement.
LITIGATION
In the ordinary course of its business, the Company is subject to legal
proceedings, claims and liabilities, including product liability matters. In
the opinion of management, the amount of ultimate liability with respect to any
known proceedings or claims will not materially affect the financial position
or results of operations of the Company.
LEASE COMMITMENTS
Future minimum rentals under noncancelable operating leases for manufacturing
and office facilities and equipment at December 31, 1996 are as follows (in
thousands):
1997 $ 550
1998 453
1999 434
2000 432
Thereafter 949
------
$2,818
======
Rent expense was $674,000, $649,000 and $537,000 in 1996, 1995 and 1994,
respectively.
F-13
34
The lease for the Company's principal office and manufacturing facility, which
was extended and now expires January 31, 2003, provides a right to extend the
lease for an additional five years at the fair market lease rate of the facility
on the extension date, but not less than the rate paid by the Company during the
month immediately preceding the commencement of the extension period.
6. SUBSEQUENT EVENT
In January 1997, the Company signed a letter of intent to sell substantially
all the assets of Dental to Steri-Oss, Inc. of Yorba Linda, California.
Consummation of the transaction is contingent upon certain conditions including
satisfactory completion of due diligence, negotiation of a mutually acceptable
definitive agreement, and the approval of the boards of directors of the
Company and Steri-Oss, Inc.
7. QUARTERLY RESULTS (UNAUDITED)
The following table presents a summary of the quarterly results of operations
for 1996 and 1995:
Quarter
------------------------------------------------------
(in thousands, except per share data) First Second Third Fourth
- ------------------------------------- ------ ------ ------ ------
1996
Net sales $4,996 $4,892 $4,733 $5,296
Gross profit 3,590 3,620 3,352 3,712
Net income 175 117 127 239
Net income per share $ .02 $ .02 $ .02 $ .03
1995
Net sales $4,248 $4,301 $4,392 $4,162
Gross profit 3,042 3,263 3,110 2,890
Net income 438 448 369 783(1)
Net income per share $ .06 $ .06 $ .05 $ .10
- ------------------
(1) During the fourth quarter of 1995, the Company recorded a $411,000
provision for distributor returns to reflect the estimated value of
product returns the Company would accept from distributors terminated as
of December 31, 1995. A $1.5 million credit was recorded in the fourth
quarter of 1995 to reflect the reduction in the valuation allowance
against deferred tax assets.
F-14
35
Interpore International
Schedule II- Valuation and Qualifying Accounts
Years ended December 31, 1996, 1995 and 1994
BALANCE AT BALANCE AT
BEGINNING ADDITIONS END OF
DESCRIPTION OF PERIOD (DEDUCTIONS) WRITE-OFFS PERIOD
-------------- --------- ------------ ---------- ----------
Year ended December 31, 1996:
Accounts receivable allowance
for doubtful accounts $523,000 $(126,000) $ 58,000 $339,000
Inventory reserve for excess
and obsolescence 281,000 489,000 - 770,000
Year ended December 31, 1995:
Accounts receivable allowance
for doubtful accounts 508,000 80,000 65,000 523,000
Inventory reserve for excess
and obsolescence 200,000 120,000 39,000 281,000
Year ended December 31, 1994:
Accounts receivable allowance
for doubtful accounts 400,000 108,000 - 508,000
Inventory reserve for excess
and obsolescence 350,000 121,000 271,000 200,000
36
EXHIBIT INDEX
Sequentially
Exhibit Numbered
Number Description Page
------ ----------- ------------
3.01 Third Amended and Restated Articles of Incorporation of Registrant,
executed on December 9, 1991(1)
3.02 First Amendment to the Third Amended and Restated Articles of
Incorporation of Registrant, executed on April 22, 1992(1)
3.03 Second Amendment to Third Amended and Restated Articles of Incorporation
of Registrant, executed on November 30, 1993(5)
3.04 Bylaws of Registrant dated October 24, 1983(1)
3.05 Third Amendment to Third Amended and Restated Articles of Incorporation
of Registrant, executed on November 30, 1993(5)
4.01 Rights Agreement dated August 29, 1995(6)
4.02 First Amendment to the Rights Agreement, executed on November 1, 1995(8)
10.01 Revised License Agreement dated March 12, 1984, between Registrant and
Research Corporation Technologies, Inc., as amended by a First Amendment
dated December 7, 1984, and as further amended by a Fourth Amendment
dated July 22, 1988(1)
10.02 Single Tenant Lease dated July 25, 1991 between Registrant and The Irvine
Company(1) as amended by a Third Amendment to Lease dated December 11,
1996.
10.03 Koll Business Center Lease between Registrant and Airport Industrial
Park(1)
10.04 Asset Purchase Agreement dated March 1, 1993 regarding sale of assets of
Interpore Orthopaedics, Inc. to Applied Epigenetics, Inc.(1)
10.05 Cancellation and Release Agreement dated March 1, 1993 among Registrant,
Interpore Orthopaedics, Inc., Pfizer, Inc. and Howmedica, Inc.(1)
10.06 Series E Preferred Stock and Common Stock Warrant Purchase Agreement
dated December 19, 1991(1)
10.07 Series E Preferred Stock Purchase Agreement dated October 30,
1992(1)
10.08 Amended Schedule to Loan and Security Agreement dated July 25, 1996 among
Registrant, Interpore Orthopaedics, Inc. and Silicon Valley Bank(9)
10.09 Amendment to the Loan Agreement dated July 25, 1996 among Registrant,
Interpore Orthopaedics, Inc. and Silicon Valley Bank(9)
37
Sequentially
Exhibit Numbered
Number Description Page
------ ----------- ------------
10.10 Amended and Restated Stock Option Plan dated March 19, 1991(2), First
Amendment to the Amended and Restated Stock Option Plan, effective
October 15, 1991(1); Amendment to the Amended and Restated Stock Option
Plan dated September 17, 1994(4)
10.11 Employee Qualified Stock Purchase Plan(3)
10.12 1995 Stock Option Plan(3)
10.13 Stock Option Plan for Non-Employee Directors of Interpore International(7)
10.14 Form of Indemnification Agreement(1)
11.01 Computations of Net Income per Share
23.01 Consent of Ernst & Young LLP, independent auditors
27.01 Financial Data Schedule
- --------------------
(1) Incorporated by reference from the Company's Registration Statement on
Form S-1, Registration No. 33-69872.
(2) Incorporated by reference from the Company's Registration Statement on
Form S-8, Registration No. 33-77426.
(3) Incorporated by reference from the Company's Proxy Statement for the
Company's 1994 Annual Meeting of Shareholders.
(4) Incorporated by reference from the Company's Registration Statement on
Form S-8, Registration No. 33-86290.
(5) Incorporated by reference from the Company's Annual Report on Form
10-K for the year ended December 31, 1994.
(6) Incorporated by reference from the Company's Current Report on Form
8-K dated August 29, 1995.
(7) Incorporated by reference from the Company's Proxy Statement for the
Company's 1995 Annual Meeting of Shareholders.
(8) Incorporated by reference from the Company's Annual Report on Form
10-K for the year ended December 31, 1995.
(9) Incorporated by reference from the Company's Quarterly Report on Form
10-Q for the fiscal quarter ended June 30, 1996.